All Updates

All Updates

icon
Filter
Funding
Navigator Medicines raises USD 100 million in Series A funding to develop NAV-240 drug candidate for inflammatory diseases
Precision Medicine
Aug 27, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Product updates
Akselos introduces software for FPSO monitoring
Digital Twin
Yesterday
Funding
Operant AI raises USD 10 million in Series A funding to boost runtime protection
Next-gen Cybersecurity
Yesterday
Funding
Aembit raises USD 25 million in Series A funding to advance IAM solutions
Identity & Access Management
Yesterday
Product updates
Saviynt launches Intelligence Suite for identity security
Identity & Access Management
Yesterday
Geographic expansion
Partnerships
FarmWise partners with RDO Equipment Co. to expand AI-powered weeding technology for vegetable growers
Smart Farming
Yesterday
Management news
Alberta Food Security Inc. receives USD 5 million order for indoor farming technology
Vertical Farming
Yesterday
Partnerships
AutoStore enhances microfulfilment offering with new grid capabilities and multi-temperature solution
Logistics Tech
Yesterday
Product updates
OpenAI launches o1, a self-fact-checking AI model
Generative AI Applications
Yesterday
Precision Medicine

Precision Medicine

Aug 27, 2024

Navigator Medicines raises USD 100 million in Series A funding to develop NAV-240 drug candidate for inflammatory diseases

Funding

  • Navigator Medicines has raised USD 100 million in a Series A funding round led by RA Capital Management and Forbion.

  • The funds raised will be used to in-license NAV-240 and an OX40L-targeted portfolio from IMBiologics. NAV-240, formerly known as IMB101, is a bispecific antibody against OX40L and TNFα, two clinically validated inflammatory disease targets. 

  • Navigator Medicines, a subsidiary of Sera Medicines, is a biotech company focused on developing biologics for targeted immune regulation and restoration. The company primarily focuses on creating new therapies for patients with complex, heterogeneous autoimmune diseases. Its lead product candidate is NAV-240, a clinical-stage bispecific antibody targeting OX40L and TNFα, two clinically validated targets critical in the pathogenesis of several inflammatory diseases. This dual-targeting approach aims to develop therapies for complex autoimmune conditions with unmet medical needs.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.